Диссертация (1140088), страница 20
Текст из файла (страница 20)
Assessment of the psoriatictranscriptome in a large sample: additional regulated genes and comparisons with invitro models.// J Invest Dermatol.- 2010.- v.130(7).-р.1829-1840.72. Guiducci C, Ott G, Chan JH et al. Properties regulating the nature of theplasmacytoid dendritic cell response to Toll-like receptor 9 activation.// J.Exp.Med.2006.-№ 203.-р. 1999-2008.73.
Gupta MA, Gupta AK, Watteel GN Perceived deprivation of social touch inpsoriasis is associated with greater psychologic morbidity: an index of the stigmaexperience in dermatologic disorders.// Cutis.-1998.-№ 61.-р. 339–342.11674. Harper EG, Guo C, Rizzo H et al. Th17 cytokines stimulate CCL20 expressionin keratinocytes in vitro and in vivo: implication for psoriasis pathogenesis.//J.Invest.Dermatol.- 2009.
-№129.-р. 2175-2183.75. Hasan M, Ruksznis C, Wang Y et al. Antimicrobial peptides inhibit polyinosinicpolycytidilic acid-induced immune responses.// J.Immunol. -2011. -№187.-р. 56535659.76. Heilborn JD, Nilsson MF, Kratz G et al. The cathelicidin anti-microbial peptideLL-37 is involved in re-epithelization of human skin wounds and is lacking inchronic ulcer epithelium.// J.Invest.Dermatol.- 2003.-№ 120.-р. 379-389.77. Hida S, Ogasawara K, Sato K et al. CD8(+) T cell-mediated skin disease in micelacking IRF-2, the transcriptinal attenuator of interferon-alpha/beta signaling.//Immunity.- 2000.-№ 13.-р. 643-655.78..Hofer A, Hassan AS, Legat FJ et al.
Optimal weekly frequency of 308-nmexcimer laser treatment in vitiligo patients.// Br J Dermatol.- 2005.-№ 152.-р. 981985.79. Horn EJ, Fox KM, Patel V et al. Are patients with psoriasis undertreated?Results of National Psoriasis Foundation survey.// Journal of the AmericanAcademy of Dermatology.-2007.-№ 57.-р. 957–962.80. Hornung V, Ablasser A, Charrel-Dennis M et al. AIM2 recognizes cytosolicdsDN and forms a caspase-1-activating inflammasome with ASC.// Nature.- 2009.-№458.-р.
514-519.81.HurtadoP,ChenAP.LL-37promotesrapidsensingofCpGoligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells.//J.Immunol.- 2010. -№184. –р.1425-1435.82. Hwang YJ, Jung HJ, Kim MJ et al.Serum levels of LL-37 and inflammatorycytokines in plaque and guttate psoriasis.// Mediators Inflamm. -2014. -2014.р.268257.83.
Ivanov II, Zhou L, Littman DR. Transcriptional regulation of Th17celldifferentiation.// Semin.Immiunol.- 2007. -№19.-р. 409-417.11784. Johansen C, Moeller K, Kragballe K,et al. The activity of caspase-1 is increasedin lesional psoriaticdermis.// J.Invest.Dermatol.- 2007.-№ 127.-р. 2857-2864.85.
Johansson J, Gudmundsson GH, Rottenberg ME et al. Conformation-dependentantibacterial activity o the naturally occurring human peptide LL-37. //J.Biol.Chem.1998.-№ 273.-р. 3718-372486. Jukić Z, Rucević I, Barisić-Drusko V, et al. Historical development of localtherapy of psoriasis vulgaris. // Acta Dermatovenerol Croat. – 2004 – v.12 - № 3 –р.191-19587. .Kahlenberg JM,Kaplan MJ. Little peptide, big effects: the role of LL-37 ininflammation and autoimmune disease.// J.Immunol.-2013,-v. 191(10).-р. 48954901.88. Karrer S, Eholzer C, Ackermann G,et al.. Phototherapy of psoriasis:Comparative experience of different phototherapeutic approaches.// Dermatology .2001.-№ 202.-р. 108-115.89.
Khan D, Ansar Ahmed S. Regulation of IL-17 in autoimmune diseases bytranscriptional factors and microRNAs.// Front Genet.- 2015.-№ 6.-р.236.90. Kim IH1, West CE, Kwatra SG et al. Comparative efficacy of biologics inpsoriasis: a review.// Am J Clin Dermatol.- 2012.- v.13(6).-р.365-374.91. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundationclinical consensus on psoriasis comorbidities and recommendations for screening.//J Am Acad Dermatol.- 2008.-№58.-р.1031-1042.92.
Kimball AB, Yu AP, Signorovitch J et al. The effects of adalimumab treatmentand psoriasis severity on self-reported work productivity and activity impairment forpatients with moderate to severe psoriasis.// J Am Acad Dermatol .-2012.-№66.e67–76.93.Krueger G The impact of psoriasis on quality of life: Results of a 1998 NationalPsoriasis Foundation patient-membership survey.// Arch Dermatol.
- 2001,-№137.р.280.94. Lande R, Gregorio J, Facchinetti V et al. Plasmacytoid dendritic cells sense selfDNA coupled with antimicrobial peptide.// Nature.- 2007.-№ 449.-р. 564-569.11895. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinicalfeatures, and quality of life. // Ann Rheum Dis. - 2005 – v.64 ( Suppl 2).-ii18-2396. Lapolla W, Yentzer BA, Bagel J et al. A review of phototherapy protocols forpsoriasis treatment.
// J Am Acad Dermatol.- 2011,-v. 64(5).-р.936-949.97. Lebwohl A. New developments in the treatment of psoriasis//Arch. Dermatol.2002.-v.l38.-№5.-р. 686-688.98. Lee PHA, Ohtake T, Zaiou M et al. Expression of an additional cathelicidinantimicrobial peptide protects against bacterial skin infection.// PNAS.- 2005.-№102. –р.3750-3755.99. Lee Y. A., Ruschendorf F., Windemuth C. et al.
Genomewide scan in germanfamilies reveals evidence for a novel psoriasissusceptibility locus on chromosome19pl3.// Am J Hum Genet.- 2000 - .6v7 - № 4.-р. 1020-1024.100. Lewis-Beck C, Abouzaid S, Xie L et al. Analysis of the relationship betweenpsoriasis symptom severity and quality of life, work productivity, and activityimpairment among patients with moderate-tosevere psoriasis using structuralequation modeling. // Patient Prefer Adherence.- 2013.-№7.-р.199-205.101. Li XB, Zang ZR, Schluesener HJ et al.
Role of exosomes in immuneregulation.// J.Cell.Mol.Med.- 2006. -№10.-р. 364-375.102. Lingen RG, Körver JE, Kerkhof PC et al.Relevance of compartmentalizationof T-cell subsets for clinical improvement in psoriasis: effect of immune-targetedantipsoriatic therapies.// Br J Dermatol.- 2008.-v. 159(1).-р.91-96.103.
Lippens S, Hoste E, Vandenabeele Р et al. Cell death in the skin.// Apoptosis.2009.-№14.-р.549–569.104.Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immunesystem changes.// Genes Immun.- 2007 - v.8 - №l.-р.l-12.105. Loves MA, Chamian F, Abello MV et al. Increase an TNF-alpha and induciblenitric o xide synthase-expressing dendritic cells in psoriasis and reduction withefalizumab (anti-CD11a).// PNAS.- 2005. -№102. –р.19057-19062.119106. Ma HL, Liang S, Li J et al. IL-22 is required for Th17 cell-mediated pathologyin mouse model of psoriasis-like skin inflammation.// J.Clin.Invest. -2008.-№ 118.р. 597-607.107. Manel N, Unutmaz D, Littman DR.
The differentiation of human Th-17 cellsrequires transforming growth factor-β and induction of the nuclear receptor RORγι.//Nat.Immunol.- 2008. -№9.-р. 641-649.108. Marinoni B, Ceribelli A, Massarotti MS et al.The Th17 axis in psoriatic disease:pathogenetic and therapeutic implications.// Auto Immun Highlights. -2014.-v.5(1).-р.9-19.109.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the managementof psoriasis and psoriatic arthritis: section 4. Guidelines of care for the managementand treatment of psoriasis with traditional systemic agents.// J Am Acad Dermatol.2009.-№ 61.-р.451–485.110. Miller LS, Sorensen OE, Liu PT et al. TGF-alpha regulates TLR expression andfunction on epidermal keratinocytes.// J.Immunol. -2005.-№ 174.-р. 6137-6143.111. Mirshafiey A, Simhag A, El Rouby NM et al.T-helper 22 cells as a new playerin chronic inflammatory skin disorders.// Int J Dermatol.- 2015.-v. 54(8).-р. 880888.112. Miyakawa Y, Matsushime H.
Rapid downregulation of cyclin D1 mRNA andprotein levels by ultraviolet irradiation in murine macrophage cells.// BiochemBiophys Res Commun.- 2001.-№284.-р.71–76.113.. Monteleone G, Pallone F, McDonald TT Intereukin-21: a critical regulator ofthe balance between effector and regulatory T-cell responses.// Trends Immunol. 2008.-№ 29.-р. 290-294.114. Monteleone G, Pallone F, McDonald TT et al.
Psoriasis from pathogenesis tonovel therapeutic approaches.// Clin.Sci.- 2011. -№120.-р. 1-11.115. Morizane S, Yamasaki K, Muhleisen B et al. Cathelicidin antimicrobial peptideLL-37 in psoriasis enables keratinocyte reactivity against TRR9 ligands.//J.Invest.Dermatol.- 2012.-v. 132(1),-р. 135-143.120116. Naik SM, Cannon G, Burbach GJ et al. Human keratinocytes constitutivelyexpress interleukin-18 and secrete biologically active interleukin-18 after treatmentwith pro-inflammatory mediators and dinitrochlorobenzene.// J.Invest.Dermatol. 1999.- №113.-р. 766-772.117. Nestle FO, Curdin C, Tun-Kyi A et al. Plasmacytoid predendritic cells initiatepsoriasis through interferon-α production.//J.Exp.Med.- 2005.-№ 202.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
